@article {Clark2020.01.27.20019026, author = {Brad Clark and Nazia Alvi and Joseph Hanks and Brad Suprenant}, title = {A Pilot Study of an Esophageal Cooling Device During Radiofrequency Ablation for Atrial Fibrillation}, elocation-id = {2020.01.27.20019026}, year = {2020}, doi = {10.1101/2020.01.27.20019026}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Esophageal thermal injury is a risk of ablation of the posterior left atrium despite various devices utilized to date.Objective Evaluate the potential of a commercially-available esophageal cooling device to provide esophageal protection during left atrial catheter ablation.Methods In this pilot study, we randomized 6 patients undergoing catheter ablation for atrial fibrillation. Three patients received standard of care for our site (use of a single-sensor temperature probe, with adjunct iced-water instillation for any temperature increases \>1{\textdegree}C). Three patients received standard ablation after placement of the esophageal cooling device using a circulating water temperature of 4{\textdegree}C. All patients underwent transesophageal echocardiogram (TEE) and esophagogastroduodenoscopy (EGD) on the day prior to ablation followed by EGD on the day after.Results In the 3 control patients, one had no evidence of esophageal mucosal damage, one had diffuse sloughing of the esophageal mucosa and multiple ulcerations, and one had a superficial ulcer with large clot. Both patients with lesions were classified as Zargar 2a. In the 3 patients treated with the cooling device, one had no evidence of esophageal mucosal damage, one had esophageal erythema (Zargar 1), and one had a solitary Zargar 2a lesion. At 3-month follow-up, 1 patient in each group had recurrence of atrial fibrillation.Conclusions The extent of esophageal injury was less severe with a commercially available esophageal cooling device than with reactive instillation of ice-cold water. This pilot study supports further evaluation with a larger clinical trial.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03481023Funding StatementFunding was provided by Riverside Medical Center (Kankakee, IL) Research Department. The cooling catheters were provided by Attune Medical but no further funding was given.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable data will be provided in the manuscript without external links.}, URL = {https://www.medrxiv.org/content/early/2020/01/28/2020.01.27.20019026}, eprint = {https://www.medrxiv.org/content/early/2020/01/28/2020.01.27.20019026.full.pdf}, journal = {medRxiv} }